Skip To Main Content
Terry Chrisomalis on Muck Rack

Terry Chrisomalis

Tampa Bay
As seen in: Seeking Alpha, MSN, Flipboard, EIN News, NewsBreak, Modest Money, dontworrybuy.com
Founder of "Biotech Analysis Central" marketplace at Seeking Alpha, Biotech author at Seeking Alpha Journalist of Biotech, Follow me on Stocktwits BiopharmaPro
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Terry

Contact Terry, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Kyverna Therapeutics: 'Strong Buy' On ElevateBio Manufacturing Deal And RA Program Advancement

|
By Terry Chrisomalis
| Seeking Alpha
Summary Kyverna Therapeutics remains a 'Strong Buy' as miv-cel advances in SPS, gMG, and refractory RA with robust clinical data. Rolling BLA submission for miv-cel in SPS is underway, targeting completion by Q4 2026, supported by positive phase 2 KYSA-8 results. The manufacturing agreement with ElevateBio secures supply for miv-cel, supporting U.S. and global commercialization and future indications.
Open in Who Shared Issue with article?

Outlook: 'Hold' - Caution On LYTENAVA FDA Approval And Cash Needs

|
By Terry Chrisomalis
| Seeking Alpha
Jul 28, 2026, 1:44 PM ET, , , , , Summary Outlook Therapeutics (OTLK) receives both FDA and European approval for LYTENAVA, targeting wet AMD, but faces significant commercialization challenges. I downgrade OTLK to 'Hold' due to acute cash constraints and the urgent need for strategic funding or a partnership to support U.S. launch. LYTENAVA offers a lower-cost, ophthalmic bevacizumab alternative in a competitive $8.5B U.S. anti-VEGF retina market, but market capture remains uncertain.
Open in Who Shared Issue with article?

Forte: 'Hold' On Positive FB102 Vitiligo Treatment Data And argenx Acquisition For $2.2 Billion

|
By Terry Chrisomalis
| Seeking Alpha
Jul 27, 2026, 1:45 PM ET, , Summary Forte Biosciences is being acquired by Argenx for $2.2 billion [$77/share], capping near-term upside. FB102 demonstrated statistically significant efficacy in phase 1b vitiligo and celiac disease studies, reinforcing its 'pipeline-in-a-product' potential. Pending catalysts include phase 2 celiac disease and phase 1b alopecia areata data, but further upside is limited by the acquisition.
Open in Who Shared Issue with article?
See all 1,729 articles